Claim Missing Document
Check
Articles

Found 2 Documents
Search

Palladium (II) chloride (PdCl2) spectrophotometry to determine lipoic acid concentration in plasma and leukocytes Novian Agni Yudhaswara; Ani Retno Prijanti; Mohamad Sadikin
Acta Biochimica Indonesiana Vol. 3 No. 1 (2020): Acta Biochimica Indonesiana
Publisher : Indonesian Society for Biochemistry and Molecular Biology

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32889/actabioina.v3i1.29

Abstract

Background: Lipoic acid is a substance contained in intra and extracellular that act as a coenzyme of Pyruvate Dehydrogenase, also as an antidote, chelating agent and antioxidant. Measurement of lipoic acid is needed to determine the amount of lipoic acid that performs its functions either as a coenzyme or an antioxidant. Besides, this measurement requires a special tool such as High Performance Liquid Chromatography (HPLC) and a process that is available in rural or simple laboratories. Objective: A common and easy tool such as a spectrophotometer was conducted and could expected to be a tool of lipoic acid determination in body fluid such as plasma. Methods: Measurement of lipoic acid using spectrophotometry with UV methanol and visible PdCl2 has been tested and compared to HPLC measurement that was valid and reliable in drug measurement or pharmaceutical preparations. Results: Determination of lipoic acid in plasma and leukocytes using PdCl2 produced replicable, reliability and valid result, with high accuracy, precision and was not different from lipoic acid measurement using HPLC, p=0.99. While UV methanol was different compare to HPLC p =0.0001 or was not valid. Conclusion: The measurement of lipoic acid using PdCl2 visible method can be applied to determine the levels of lipoic acid (LA) and DHLA in plasma and equal to HPLC result.
The role and regulation of FOXO1 in carbohydrate metabolism and its targeting in metabolic diseases Ani Retno Prijanti; Ni Made Wiasty Sukanty
Indonesian Archives and Biomedical Sciences Vol 1 No 2 (2021): Indonesian Archives of Biomedical Research (InABR). 1(2): 2021
Publisher : Konsorsium Ilmu Biomedik Indonesia (KIBI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (145.708 KB) | DOI: 10.55392/indarcbiores.v1i2.8

Abstract

Carbohydrate is the first energy source used in metabolic processes. Failure in carbohydrate metabolism can cause metabolic diseases, and many studies are focused on its therapy. Until now, there is no specific therapy approved. Despite that, one of the main alternatives is regarding the involvement of FOXO1 protein in metabolic disease progress. As a transcription factor for gluconeogenesis genes, FOXO1 can increase blood glucose levels. It also involves various signaling pathways in carbohydrate metabolisms such as PI3K/Akt and PKA in which many proteins act as FOXO1 regulators through posttranslational modification. The vital role of FOXO1 in carbohydrate metabolism provides an opportunity to make FOXO1 the main target of metabolic disease therapy. Various proteins and natural compounds can either directly or indirectly regulate FOXO1 activity. It can be an option to be used to control blood glucose levels by targeting FOXO1